Eisler Capital (Us) LLC Gilead Sciences, Inc. Call Options Transaction History

Eisler Capital (Us) LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $366,245 - $461,945	5,500 Added 9.63%	62,600 $5.25 Billion
Q2 2024 Aug 13, 2024	SELL	$63.15 - $72.88 $726,225 - $838,120	-11,500 Reduced 16.76%	57,100 $3.92 Billion
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $3.29 Million - $4.01 Million	45,900 Added 202.2%	68,600 $5.02 Billion
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $1.09 Million - $1.24 Million	-14,900 Reduced 39.63%	22,700 $1.84 Billion
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $2.78 Million - $3.03 Million	37,600 New	37,600 $2.82 Billion

1,923

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Eisler Capital (Us) LLC, based on Form 13F filings with the SEC.

Stay updated on Eisler Capital (Us) LLC with notifications on news.